Integral Diagnostics (IDX) H1 2025 earnings summary

Executive summary

• Revenue for 1H FY25 increased 9.3% year-over-year to $252.9m, including $3.5m from Capitol Health post-acquisition on 20 December 2024.

• Standalone revenue grew 7.8% to $249.4m, with operating EBITDA up 8.2% to $46.8m and operating NPAT up 31.9% to $9.8m.

• Completed merger with Capitol Health, expanding the network to 150 clinics and over 350 radiologists, with integration underway and at least $10m in annual pre-tax net cost synergies expected, most realized in the first year.

• Declared a fully franked interim dividend of 2.5 cents per share, with a payout ratio of 106.1% of operating NPAT on a merged basis.

• Statutory loss after tax of $0.4m, impacted by $9.2m in transaction and integration costs and a $1.3m loss from Capitol for the period under control.

Financial highlights

• Total revenue and other income rose to $253.4m from $231.6m year-over-year.

• Operating EBITDA margin was 18.8%, up slightly from 18.7% year-over-year.

• Free cash flow grew 22.7% with 88.8% conversion (excluding replacement capital).

• Net debt increased to $298.7m, mainly due to the Capitol acquisition, with net debt/EBITDA at 2.8x (2.6x including projected synergies), down from 3.0x prior year.

• Operating diluted EPS up 14.2% to 3.6 cents per share.

Outlook and guidance

• Focus on integrating Capitol Health, targeting at least $10m in annual pre-tax net cost synergies.

• Positioned to benefit from MRI deregulation and the National Lung Cancer Screening Program starting July 2025.

• FY25 replacement and growth capex expected at $60m–$65m, including $20m for Capitol.

• Strategic priorities include organic growth, teleradiology, digital/AI, and operational improvements to drive margin expansion.